Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

Analyst Ratings

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $2.75 (64.67% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Royal Bank Of CanadaReiterated RatingSector Perform$2.00 -> $1.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/28/2015WallachBeth CapitalLower Price TargetBuy$6.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015BMO Capital MarketsReiterated RatingMarket Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit Suisse Group AGInitiated CoverageUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/9/2016Q116($0.10)($0.09)$9.02 million$9.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.13)($0.13)$8.26 million$7.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.13)($0.11)$8.87 million$9.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.14)($0.11)$10.95 million$9.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.14)($0.10)$10.56 million$12.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.12)($0.15)$10.36 million$9.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.12)($0.05)$10.90 million$8.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2014Q2 14($0.11)$0.03$9.81 million$12.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.10)($0.12)$7.98 million$6.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$0.02($0.11)$7.00 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.12)($0.08)$5.30 million$3.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.15$0.18$57.30 million$68.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2013Q1 2013$0.11$0.09$50.36 million$2.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2013Q4 2012($0.03)($0.10)$21.94 million$1.94 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.11)($0.07)$3.72 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012($0.08)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2011($0.14)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.15)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2011($0.21)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2011($0.22)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arena Pharmaceuticals (NASDAQ:ARNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
DateHeadline
07/30/16 02:39 PMTop Earnings to Watch for: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - The Voice Registrar
07/28/16 11:19 AMBiotech Stocks Worth a Closer Look: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Merrimack Pharmaceuticals, Inc ... - The Voice Registrar
07/28/16 11:19 AMAnalyst's Stocks Ratings Trend: GlaxoSmithKline PLC (NYSE:GSK) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Street Updates
07/27/16 08:20 PMArena Pharmaceuticals : Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
07/27/16 02:35 PMThe Insider Activity Don't Lie: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Review Fortune
07/26/16 12:12 PMLatest Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Target Price Suggests Stock Is Worth $3.75/Share - Review Fortune
07/26/16 10:42 AMETF’s with exposure to Arena Pharmaceuticals, Inc. : July 26, 2016 -
07/25/16 03:07 PMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives FDA’s Approval Of BELVIX XR CIV.
07/25/16 03:07 PMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives FDA’s Approval Of BELVIX XR CIV.
07/25/16 07:22 AMTwo Stocks within Analysts Review: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , Zimmer Biomet Holdings, Inc ... - Street Updates
07/23/16 02:33 PMStock Displaying Signs of a Downtrend: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Press Telegraph
07/23/16 05:37 AMEquity Roundup: Stock Performance Focus on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Press Telegraph
07/22/16 02:33 PMTwo Stocks to Watch: OpGen, Inc. (NASDAQ:OPGN) , Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Street Updates
07/21/16 02:36 PMWhich way Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insiders are heading - Review Fortune
07/21/16 02:36 PMStock Performance to Track: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - News Oracle
07/21/16 07:17 AMArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : July 21, 2016 -
07/20/16 10:02 PMTwo Stocks within Analysts Limelight: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , Calithera Biosciences, Inc ... - Street Updates
07/20/16 10:02 PMArena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for July 19 - Equities.com
07/20/16 03:47 PMSCLN Withdraws From Auction Block, ZFGN Tumbles, Double Blessing For VRX
07/20/16 03:47 PMEisai, Arena Pharma (ARNA) Announce FDA Approval of BELVIQ XR ER; Arena to Receive $10M Milestone Payment
07/20/16 10:41 AMArena Pharmaceuticals Inc Stock Technicals at Critical Inflection Point - CML News
07/20/16 10:41 AMStocks Intraday Alert: Arena Pharmaceuticals, Inc. (ARNA), Radian Group Inc. (RDN), PayPal Holdings, Inc. (PYPL) - iStreetWire
07/20/16 10:41 AMTrading the Biotech News: Celgene Corporation (NASDAQ:CELG), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - The Voice Registrar
07/20/16 09:10 AMCompany News for July 20, 2016 -
07/19/16 02:34 PMThree Movers to Watch for: Humana Inc. (HUM), Arena Pharmaceuticals, Inc. (ARNA), Clean Energy Fuels Corp. (CLNE) - iStreetWire
07/19/16 02:34 PMArena Pharma stock rises 8.8% after weight-loss drug is approved - MarketWatch
07/19/16 11:43 AMArena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug -
07/19/16 09:20 AMEisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets -
07/19/16 08:46 AMEisai, Arena Pharma (ARNA) Announce FDA Approval of BELVIQ XR ER; Arena to Receive $10M Milestone Payment - StreetInsider.com
07/19/16 08:02 AMARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events -
07/19/16 07:40 AMArena Pharma stock rises 8.8% after weight-loss drug is approved -
07/19/16 07:28 AM8:28 am Arena Pharm & Eisai (ESALY) confirm the FDA has approved the NDA for Belviq CIV extended-release 20 mg tablets; Arena to receive a $10 mln milestone payment -
07/19/16 07:26 AMEisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets - [PR Newswire] - WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets. The new formulation of lorcaserin will offer patients a once-a-day dosing option that may help them achieve and maintain weight loss. BELVIQ XR is expected to be available in the fall of 2016.
07/18/16 02:38 PMIntraday Active Biotech Stocks News: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Sarepta Therapeutics, Inc ... - The Voice Registrar
07/18/16 07:27 AMShare Performance Summary for: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Press Telegraph
07/17/16 07:20 AMNext Weeks Broker Price Targets For Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - Fiscal Standard
07/15/16 06:51 PMStocks To Watch: Nielsen Holdings plc (NLSN), Arena Pharmaceuticals, Inc. (ARNA), Unilever PLC (UL) - iStreetWire
07/15/16 06:51 PMCompany Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. and Eisai Inc. Announce Regulatory Approval of ... - Smarter Analyst
07/14/16 02:36 PMPrice Trends to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , Stryker Corporation (NYSE:SYK) - Street Updates
07/14/16 02:36 PM12 Stocks Moving In Thursday's Pre-Market Session - Benzinga
07/14/16 02:36 PMArena Pharma (ARNA), Eisai Receive Mexican Regulatory Approval for Venespri - StreetInsider.com
07/14/16 11:52 AMEisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. revealed Thursday that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has given its approval for the chronic weight management agent VENESPRI. It would proceed for commercialization by Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico) in Mexico. Arena and Eisai said that VENESPRI is currently approved in Mexico as an adjunct to a reduced-calorie diet, as well as, increased physical activity for chronic weight management ...Full story available on Benzinga.com
07/14/16 11:27 AMEisai And Arena Pharma Announce Regulatory Approval Of VENESPRI In Mexico
07/14/16 11:27 AMArena Pharmaceuticals boosted as obesity drug gets Mexican approval
07/14/16 07:38 AMEisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in Mexico - [at noodls] - WOODCLIFF LAKE, N.J. and SAN DIEGO, July 14, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary ...
07/14/16 07:21 AMArena Pharmaceuticals stock soars after weight drug approved in Mexico -
07/13/16 02:35 PMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 02:35 PMAnalyst Consideration on this Stock: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - News Oracle
07/13/16 02:35 PMArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Earns Consensus Hold Rating - Review Fortune
07/13/16 02:35 PMNotable Analysts Ratings: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , DaVita healthCare Partners Inc. (NYSE:DVA) - Street Updates

Social

About Arena Pharmaceuticals

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company's drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserin's once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Company's other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARNA
  • CUSIP: 04004710
Key Metrics:
  • Previous Close: $1.68
  • 50 Day Moving Average: $1.75
  • 200 Day Moving Average: $1.69
  • P/E Ratio: N/A
  • P/E Growth: 0.24
  • Market Cap: $405.88M
  • Beta: -0.57
  • Current Year EPS Consensus Estimate: $-0.36 EPS
  • Next Year EPS Consensus Estimate: $-0.25 EPS
Additional Links:
Arena Pharmaceuticals (NASDAQ:ARNA) Chart for Sunday, July, 31, 2016